Deka’s automated insulin delivery system, powered by patient-led app, gets FDA clearance

Sequel Med Tech will sell the new system, which integrates with Tidepool’s Loop insulin dosing algorithm.

Deka Research & Development ha received 510(k) clearance for the Twiist automated insulin delivery (AID) system, the company’s partner Sequel Med Tech said Monday.
Sequel, which will sell the system, worked with Deka and Tidepool on the product. Deka was founded by the inventor who commercialized the first wearable insulin pump. Tidepool is behind Loop, a patient-led automated insulin dosing app.
Twiist combines Deka drug delivery technology with the Loop algorithm to create what Sequel says is the first system that directly measures the volume and flow of insulin delivered with every micro-dose.

Sign up for Blog Updates